DUBLIN–(BUSINESS WIRE)–The “House Dust Mite Allergy R&D Pipeline Analysis Report, Q4 2020” report has been added to ResearchAndMarkets.com’s offering.
The Q4 House Dust Mite Allergy pipeline report is part of the immunology disease pipeline service. This quarterly review describes the pipeline of drugs under development for House Dust Mite Allergy, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.
Scope and Coverage
- House Dust Mite Allergy pipeline development activities across the early phase, mid-stage, and late phase pipelines including therapeutic candidates
- Drug profiles comprising of drug overview, mechanism of action, co-developers, originators, route of administration, molecule type, orphan drug status, new molecular entity, area, and other details.
- Company-company partnerships, company-institute partnerships, and investment details of companies are included
- 9 companies are included including Advagene Biopharma Co Ltd, ALK-Abello AS, Allergy Therapeutics Plc, Anergis SA, Biomay AG, Genetic Immunity Inc, Polyrizon Ltd, Roxall Medizin GmbH, Stallergenes Greer plc,
- Disease overview, Pipeline trends, market analysis, and other developments
- Potential licensing/new business opportunities in House Dust Mite Allergy pipeline market
Highlights
- Global coverage of companies and pipeline agents
- 2020 Trends, market analysis, and developments
- Potential growth opportunities
- Comprehensive details of drug candidates
Key report benefits:
- Drive pipeline research and commercial assessment
- Assess most promising drug candidates and stay ahead of the competition
- Strengthen your pipeline through identifying business expansion and acquisition opportunities
-
Develop new candidates based on most focused targets and mechanism of actions
Key Topics Covered:
1. Table of Contents
1.1 List of Tables
1.2 List of Figures
2. House Dust Mite Allergy Pipeline Trends and Insights
2.1 Dominant Phase type of House Dust Mite Allergy Pipeline, 2020
2.2 Most focused Mechanism of Action in House Dust Mite Allergy Pipeline
2.3 Leading type of Route of Administration during 2020
2.4 Proportion of New Molecular Entities in House Dust Mite Allergy pipeline
2.5 Active Companies Developing House Dust Mite Allergy pipeline
3. House Dust Mite Allergy Disease Types, Symptoms, Causes, and Available Treatment Options
3.1 Disease Overview
3.2 Types
3.3 Symptoms
3.4 Approved Treatment Options
4. House Dust Mite Allergy Pipeline Company Trends and Insights- Business Profiles, Drug Candidates and Contacts
- Advagene Biopharma Co Ltd
- ALK-Abello AS
- Allergy Therapeutics Plc
- Anergis SA
- Biomay AG
- Genetic Immunity Inc
- Polyrizon Ltd
- Roxall Medizin GmbH
- Stallergenes Greer plc
5. House Dust Mite Allergy Pipeline Drug Profiles
5.1 Current Status of Drug and Vaccine Candidates
5.2 Drug Snapshot
5.2.1 Drug
5.2.2 Mechanism of Action
5.2.3 Phase
5.2.4 Co-Developer
5.2.5 Originator
5.2.6 Synonym
5.2.7 Route of Administration
5.2.8 Type of Molecule
5.2.9 Orphan Drug Status
5.2.10 New Molecular Entity
5.2.11 Area
5.3 Drug Details
5.4 Mechanism of Action
5.5 Licensing/Collaboration Agreements
5.6 Clinical Trial Details
6. House Dust Mite Allergy Pipeline Market News and Developments during 2020
7. Appendix
For more information about this report visit https://www.researchandmarkets.com/r/f0xobr
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900